A detailed history of Ancora Advisors, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Ancora Advisors, LLC holds 151 shares of MRNA stock, worth $5,564. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151
Previous 239 36.82%
Holding current value
$5,564
Previous $28,000 64.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$63.64 - $125.14 $5,600 - $11,012
-88 Reduced 36.82%
151 $10,000
Q2 2024

Aug 14, 2024

BUY
$101.21 - $166.61 $303 - $499
3 Added 1.27%
239 $28,000
Q4 2023

Feb 14, 2024

SELL
$69.51 - $104.43 $4,865 - $7,310
-70 Reduced 22.88%
236 $23,000
Q2 2023

Aug 14, 2023

SELL
$118.5 - $160.53 $2,725 - $3,692
-23 Reduced 6.99%
306 $37,000
Q1 2023

May 15, 2023

BUY
$135.66 - $197.02 $13,023 - $18,913
96 Added 41.2%
329 $50,000
Q3 2022

Nov 14, 2022

BUY
$118.07 - $194.18 $1,652 - $2,718
14 Added 6.39%
233 $28,000
Q2 2022

Aug 15, 2022

SELL
$117.13 - $176.59 $117 - $176
-1 Reduced 0.45%
219 $31,000
Q1 2022

May 16, 2022

SELL
$126.46 - $235.05 $56,401 - $104,832
-446 Reduced 66.97%
220 $38,000
Q1 2022

May 13, 2022

BUY
$126.46 - $235.05 $56,401 - $104,832
446 Added 202.73%
666 $87,000
Q4 2021

Feb 14, 2022

BUY
$225.82 - $368.51 $903 - $1,474
4 Added 1.85%
220 $56,000
Q3 2021

Nov 15, 2021

SELL
$221.9 - $484.47 $122,045 - $266,458
-550 Reduced 71.8%
216 $83,000
Q2 2021

Aug 13, 2021

BUY
$129.91 - $234.98 $12,991 - $23,498
100 Added 15.02%
766 $180,000
Q1 2021

May 14, 2021

BUY
$109.18 - $185.98 $109 - $185
1 Added 0.15%
666 $87,000
Q3 2020

Nov 13, 2020

BUY
$54.34 - $94.85 $6,249 - $10,907
115 Added 20.91%
665 $47,000
Q1 2020

May 14, 2020

BUY
$17.78 - $31.58 $9,779 - $17,369
550 New
550 $16,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Ancora Advisors, LLC Portfolio

Follow Ancora Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ancora Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ancora Advisors, LLC with notifications on news.